Our clients

John Orloff,
Executive Vice President, Head of Research & Development, Alexion Pharmaceutical

« SYNOV was instrumental to the successful design and roll-out of our new, state-of-the art, program team operating model and governance framework. Their deep experience in program leadership and cross-functional teamwork proved invaluable to its smooth implementation, allowing us to effectively advance a portfolio that is growing rapidly in breadth and complexity. And their attention to cultural barriers and change management will ensure a sustainable model over time. I highly recommend this team to any organization looking for impactful change that will drive lasting value. »

Chris Benecchi,
Global Head of Commercial Excellence, Alexion Pharmaceuticals

« From our initial meeting with the Synov Team, their deep functional expertise which enables organizations to build high-performing drug development teams and processes to accelerate delivery of product to patients was readily apparent. But their impact extended well beyond these areas. As a commercial leader with significant experience in working with therapies in all phases of development, I was impressed with the insight the Synov Team brought to the table that connected the underlying need to operate more effectively to the downstream go-to-market impact such efforts would have. Synov understood the implications structural and process changes could have on our HCPs, patients, payers, and policy makers and embedded that insight into the way they guided us on our approach to ensure that the needs of all stakeholders at every point in the development and commercialization process could be taken into consideration and actioned most effectively. »

Simone Lauchart,
Vice President, Head R&D Strategy, Program and Portfolio Management, Alexion Pharmaceuticals

« SYNOV Solutions joined our team and took immediate action in implementing our new business operating model. Their contributions and thoughtful approach ensured that not only the « what » and the ‘how” but also the « why » of our approach became well understood and lived! Additionally, their approach to team training is quite unique and had a huge positive impact on the willingness of our teams to embrace our new operating model. « 

Tom Anderson,
CEO, SwanBio Therapeutics

« SYNOV has been an outstanding partner for SwanBio. Their extensive experience and knowledge of gene therapy development benefitted us greatly in our early days as a startup and is carrying through to our becoming a clinical stage company. SYNOV worked seamlessly with our Research, Tech Ops and Clinical teams while helping to embed our operating model. SYNOV was able to work at all levels of the organization including our Leadership Team and Board of Directors. It is an absolute pleasure to work with SYNOV and would highly recommend them to prospective clients. »

Carolyn Carroll,
CPO, SwanBio Therapeutics

« SYNOV is a team of seasoned experts in drug development working with emerging companies to set up the foundational structure, processes and operating model. What they helped us build at SwanBio will be in place for years to come because they do it with the line of sight to be scalable. As the Chief People Officer, I found SYNOV’s areas of expertise to be in concert with mine and they were a welcomed partner in the starting phase of our growth. Working with SYNOV has been a true collaboration and they are well versed in operating at all levels of the company, from designing and executing the operating model to working with the leadership team on organizational and operational strategy. They have been, and continue to be, a pleasure to work with. »

Annalisa Jenkins,
CEO, Dimension Therapeutics

« SYNOV Solutions came into Dimension Therapeutics to provide us with development team leadership support as we were navigating an exciting innovative portfolio of gene therapy products growing rapidly in a competitive space. Their ability to bring together the functions to drive forward a robust integrated development plan and ensure operational execution was exemplary. They helped the company set up the programs for the success and the data today that are now moving the assets into pivotal studies towards registration. »

Eric Crombez, MD
CMO, Ultragenyx Gene Therapy and former CMO, Dimension Therapeutics

“SYNOV Solutions came on board during a rapid growth and transition phase of our organization and supported the transition of our lead programs from research to the clinic. SYNOV Solutions was a collaborative partner to the Leadership Team and helped progress our team’s mindset to a cross functional and collaborative model needed to successfully manage the complexity of rare disease drug development. Their experience and acumen in drug development and organizational effectiveness ensured a smooth change management process that is lasting to this date.”

Rachel Humphrey,
Former CMO, CytomX Therapeutics

« SYNOV transformed the way our program teams operated, bringing true cross functional plans to fruition and clear leadership for enhanced decision making at the portfolio level. »